Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04458909
Title Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

nasopharynx carcinoma

Therapies

Cisplatin + Gemcitabine + Nivolumab

Cisplatin + Gemcitabine

Carboplatin + Gemcitabine

Carboplatin + Gemcitabine + Nivolumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.